Precigen, Inc. Share Price

Equities

PGEN

US74017N1054

Pharmaceuticals

Real-time Estimate Cboe BZX 11:10:29 17/06/2024 pm IST 5-day change 1st Jan Change
1.645 USD +0.92% Intraday chart for Precigen, Inc. -3.53% +22.39%
Sales 2024 * 50.2L 42Cr Sales 2025 * 4.32Cr 360.98Cr Capitalization 41Cr 3.44TCr
Net income 2024 * -9.6Cr -801.48Cr Net income 2025 * -7.6Cr -634.51Cr EV / Sales 2024 * 65.2 x
Net cash position 2024 * 8.4Cr 701.3Cr Net cash position 2025 * 11Cr 943.41Cr EV / Sales 2025 * 6.9 x
P/E ratio 2024 *
-4.5 x
P/E ratio 2025 *
-5.98 x
Employees 202
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.41%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Precigen, Inc.

1 day-4.12%
1 week+0.62%
Current month+16.43%
1 month+16.43%
3 months+13.99%
6 months+33.61%
Current year+21.64%
More quotes
1 week
1.61
Extreme 1.61
1.74
1 month
1.30
Extreme 1.3
1.83
Current year
1.19
Extreme 1.19
1.83
1 year
0.84
Extreme 0.8354
1.88
3 years
0.81
Extreme 0.805
6.96
5 years
0.81
Extreme 0.805
11.10
10 years
0.81
Extreme 0.805
69.45
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 01/20/01
Director of Finance/CFO 62 01/21/01
Chairman 70 01/08/01
Members of the board TitleAgeSince
Chairman 70 01/08/01
Director/Board Member 68 01/09/01
Corporate Officer/Principal 52 01/14/01
More insiders
Date Price Change Volume
17/24/17 1.635 +0.31% 242 296
14/24/14 1.63 -4.12% 601,194
13/24/13 1.7 +1.80% 661,203
12/24/12 1.67 +1.83% 637,470
11/24/11 1.64 -3.53% 611,546

Delayed Quote Nasdaq, June 15, 2024 at 01:30 am IST

More quotes
Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Company’s proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Company's legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. Exemplar segment is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar (Exemplar), its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.63 USD
Average target price
10.12 USD
Spread / Average Target
+521.06%
Consensus
1st Jan change Capi.
+21.64% 41Cr
+41.54% 63TCr
-7.15% 35TCr
+18.77% 33TCr
+8.79% 30TCr
+17.91% 25TCr
+0.29% 22TCr
+10.59% 22TCr
+3.68% 16TCr
-4.38% 16TCr
Other Pharmaceuticals